149 related articles for article (PubMed ID: 21478328)
1. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.
Pritchett Y; Jemiai Y; Chang Y; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata-Andía JB; Thompson T; Appelbaum E; Audhya P; Andress D; Zhang W; Solomon S; Manning WJ; Thadhani R
Clin Trials; 2011 Apr; 8(2):165-74. PubMed ID: 21478328
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
Thadhani R; Appelbaum E; Pritchett Y; Chang Y; Wenger J; Tamez H; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Packham D; Singh B; Zehnder D; Shah A; Pachika A; Manning WJ; Solomon SD
JAMA; 2012 Feb; 307(7):674-84. PubMed ID: 22337679
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.
Tamez H; Zoccali C; Packham D; Wenger J; Bhan I; Appelbaum E; Pritchett Y; Chang Y; Agarwal R; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Singh B; Zehnder D; Pachika A; Manning WJ; Shah A; Solomon SD; Thadhani R
Am Heart J; 2012 Dec; 164(6):902-9.e2. PubMed ID: 23194491
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.
Panizo S; Barrio-Vázquez S; Naves-Díaz M; Carrillo-López N; Rodríguez I; Fernández-Vázquez A; Valdivielso JM; Thadhani R; Cannata-Andía JB
Nephrol Dial Transplant; 2013 Nov; 28(11):2735-44. PubMed ID: 24013683
[TBL] [Abstract][Full Text] [Related]
5. Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.
Pérez V; Sánchez-Escuredo A; Lauzurica R; Bayés B; Navarro-Muñoz M; Pastor MC; Cañas L; Bonet J; Romero R
Eur J Pharmacol; 2013 Jun; 709(1-3):72-9. PubMed ID: 23567070
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.
Thadhani R; Appelbaum E; Chang Y; Pritchett Y; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson T; Audhya P; Andress D; Zhang W; Ye J; Packham D; Singh B; Zehnder D; Manning WJ; Pachika A; Solomon SD
Am J Nephrol; 2011; 33(2):139-49. PubMed ID: 21242674
[TBL] [Abstract][Full Text] [Related]
7. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
8. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
[TBL] [Abstract][Full Text] [Related]
9. Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial.
Lundwall K; Jörneskog G; Jacobson SH; Spaak J
Am J Nephrol; 2015; 42(4):265-73. PubMed ID: 26496210
[TBL] [Abstract][Full Text] [Related]
10. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
11. Paricalcitol and endothelial function in chronic kidney disease trial.
Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F
Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743
[TBL] [Abstract][Full Text] [Related]
12. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.
Duplancic D; Cesarik M; Poljak NK; Radman M; Kovacic V; Radic J; Rogosic V
Clin Interv Aging; 2013; 8():149-56. PubMed ID: 23430986
[TBL] [Abstract][Full Text] [Related]
13. Effect of active vitamin-D on left ventricular mass index: Results of a randomized controlled trial in type 2 diabetes and chronic kidney disease.
Gnudi L; Fountoulakis N; Panagiotou A; Corcillo A; Maltese G; Rife MF; Ntalas I; Franks R; Chiribiri A; Ayis S; Karalliedde J
Am Heart J; 2023 Jul; 261():1-9. PubMed ID: 36934979
[TBL] [Abstract][Full Text] [Related]
14. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
Matuszkiewicz-Rowińska J; Żebrowski P
Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
[TBL] [Abstract][Full Text] [Related]
15. The impact of paricalcitol on left ventricular hypertrophy.
Cozzolino M; Ronco C
Contrib Nephrol; 2011; 171():161-165. PubMed ID: 21625106
[TBL] [Abstract][Full Text] [Related]
16. Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy.
Fedele F; Frati G; Biondi-Zoccai G
Int J Cardiol; 2013 Sep; 167(5):2343-4. PubMed ID: 23176772
[No Abstract] [Full Text] [Related]
17. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
[TBL] [Abstract][Full Text] [Related]
18. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
20. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
